Podium Presentation
Where: Pharma CI Europe 2026, Frankfurt, Germany
When: Thursday April 30, 2026; 11:00 AM CEST
In recent years, China has become a global leader in oncology and immunology innovation, and a key player in the commercial market for multinational pharma; however, it remains a persistent CI blind spot. It’s where early oncology and immunology signals emerge first and often stay hidden.
At Pharma CI Europe 2026, we’re diving into this critical gap. In this session, we’ll explore:
- Why standard global CI frameworks fall short in China
- How to uncover early signals from local and non-traditional sources
- The impact of evolving regulatory and access dynamics
- How leading organizations are making China a central pillar of their CI strategy
This session sets out a practical framework for moving China from a regional afterthought to a central pillar of your global CI capability, actively driving insights and strategic decisions.
ABOUT THE EVENT
competitive intelligence (CI), business strategy and analytics professionals within the pharmaceutical, biotechnology and medical device industries.
Find us at Booth at The Westin Grand Frankfurt, Germany.
Let’s discuss how we can:
- Monitor the competitive landscape with precision
- Uncover hidden signals in complex data
- Enable faster, smarter and more strategic decision making
- Stay ahead of the curve to sharpen your edge in the competition
We look forward to seeing you there!
MEET THE EXPERTS
Cameron Mackenzie
Vice President, Competitive Strategy
Cameron Mackenzie, PhD, MBA, brings two decades of biopharma leadership to his role as Vice President. By bridging the gap between R&D and business development, he delivers cross-functional strategy and drives high-value results for Prescient’s clients.
Arafa Salam
Associate Director, Competitive Strategy
Arafa brings over a decade of experience and possesses deep expertise in crafting competitive strategies, enhancing client engagement, and delivering measurable impact for Prescient’s clients.
The Uptake Launch Excellence Report 2026
